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Abstract
Drug-induced toxicity is a key issue for public health because some side effects
can be severe and life-threatening. These adverse effects can also be a major
concern for the pharmaceutical companies since significant toxicity can lead to
the interruption of clinical trials, or the withdrawal of the incriminated drugs
from the market. Recent studies suggested that endoplasmic reticulum (ER)
stress could be an important event involved in drug liability, in addition to
other key mechanisms such as mitochondrial dysfunction and oxidative stress.
Indeed, drug-induced ER stress could lead to several deleterious effects within
cells and tissues including accumulation of lipids, cell death, cytolysis, and
inflammation. After recalling important information regarding drug-induced
adverse reactions and ER stress in diverse pathophysiological situations, this
review summarizes the main data pertaining to drug-induced ER stress and its
potential involvement in different adverse effects. Drugs presented in this
review are for instance acetaminophen (APAP), arsenic trioxide and other anti-
cancer drugs, diclofenac, and different antiretroviral compounds. We also
included data on tunicamycin (an antibiotic not used in human medicine
because of its toxicity) and thapsigargin (a toxic compound of the Mediter-
ranean plant Thapsia garganica) since both molecules are commonly used as
prototypical toxins to induce ER stress in cellular and animal models.
Abbreviations
APAP, acetaminophen; CHOP, C/EBP homologous protein; COX, cyclooxygenase;
CYP, cytochrome P450; ER, endoplasmic reticulum; GI, gastrointestinal; GRP, glucose-
related protein 78; GSH, glutathione; NAPQI, N-acetyl-p-benzoquinone imine; NRTI,
nucleoside reverse transcriptase inhibitor; NSAID, nonsteroidal anti-inflammatory
drug; 4-PBA, 4-phenylbutyrate; PERK, PKR-like ER kinase; PI, protease inhibitor;
PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species;
SREBP, sterol regulatory element-binding protein; UPR, unfolded protein response.
Introduction
Drug-induced toxicity is an important issue for public
health and the well-being of patients. Indeed, some side
effects can be severe and require a hospitalization, or even
can cause the death of some patients. These adverse
effects can also be a major concern for the pharmaceutical
companies because significant toxicity can lead to the
interruption of clinical trials, or the withdrawal of the
incriminated drugs from the market (Labbe et al. 2008;
Elangbam 2010). In the recent years, the endoplasmic
reticulum (ER) stress emerged as a potential important
event involved in drug liability, in addition to other key
mechanisms such as mitochondrial dysfunction and
oxidative stress. Thus, the main objective of the present
review was to collect the available information regarding
drug-induced ER stress and its potential role in the
occurrence of different adverse reactions. For this pur-
pose, we performed a PubMed search of literature pub-
lished in the English language using the following queries
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(by alphabetical order): adverse effect, adverse event,
adverse reaction, drug, drug-induced, ER stress, and toxic-
ity. This data mining was also completed by using Google
Scholar. Besides the different drugs presented below, we
also included data on tunicamycin and thapsigargin since
both molecules are commonly used as prototypical toxins to
induce ER stress in cellular and animal models.
Drug-Induced Adverse Effects and Main
Mechanisms of Toxicity
Many drugs of our modern pharmacopeia are able to
induce adverse effects that can involve different tissues
such as the liver, heart, kidney, lung, skeletal muscles, adi-
pose tissue, and peripheral nerves (Marrer and Dieterle
2010; Begriche et al. 2011; Hohenegger 2012; Tocchetti
et al. 2013; Miltenburg and Boogerd 2014). Notably, a
single drug can damage several tissues in the same patient
and induce several types of lesions in a given tissue. For
instance, drug-induced liver injury includes hepatic cytol-
ysis, autoimmune-like hepatitis, cholestasis, steatosis,
steatohepatitis, cirrhosis, and hepatocellular adenoma
(Wang et al. 2013a; Leise et al. 2014). This variety of liver
lesions actually reflects the occurrence of different mecha-
nisms of toxicity and the potential involvement of several
types of hepatic cells such as hepatocytes, cholangiocytes,
stellate cells, activated lymphocytes, and Kupffer cells
(Stirnimann et al. 2010; Czaja 2011; Padda et al. 2011).
It is currently acknowledged that mitochondrial dys-
function and oxidative stress are two major mechanisms
whereby drugs can induce injuries in different tissues
such as the liver, heart, and kidney (Sardao et al. 2008;
John and Herzenberg 2009; Baillie and Rettie 2011;
Begriche et al. 2011; Deavall et al. 2012; Tocchetti et al.
2013; Miltenburg and Boogerd 2014). Actually, drugs can
induce oxidative stress via several mechanisms including
by increasing reactive oxygen species (ROS) production
by the dysfunctional mitochondria and higher NADPH
oxidase activity and by reducing cellular antioxidant
defenses (Labbe et al. 2008; Baillie and Rettie 2011;
Begriche et al. 2011; Leung et al. 2012).
Drugs can be harmful either directly or indirectly after
their biotransformation into one or several toxic reactive
metabolites by cellular enzymes such as cytochromes P450
(CYPs) (Baillie and Rettie 2011; Begriche et al. 2011;
Leung et al. 2012). Importantly, CYPs and other xenobi-
otic metabolizing enzymes (XMEs) are expressed mainly
in the liver but also in other tissues including the gas-
trointestinal (GI) tract, kidney, lung, brain, heart, and
white adipose tissue (Dutheil et al. 2009; Thelen and
Dressman 2009; Ellero et al. 2010; Knights et al. 2013;
Ravindranath and Strobel 2013). Hence, the generation of
toxic reactive metabolites can occur in liver and extra-
hepatic tissues (Gu et al. 2005; Ding and Kaminsky
2003). Finally, besides mitochondrial dysfunction and
oxidative stress, there is increasing evidence that ER stress
can be another important mechanism in drug-induced
adverse effects, as underlined in this review.
Definition and Cellular Consequences of ER
Stress
The ER plays a crucial role in the synthesis of all the pro-
teins that are secreted from cells, or inserted into organelle
membranes. Efficient protein folding in the ER requires a
tight coupling between the arrival of new proteins in the ER
lumen and the ER folding capacity. Efficient folding
requires ER-resident proteins such as chaperones and fol-
dases that are calcium-binding/buffering proteins (Coe and
Michalak 2009; Halperin et al. 2014). These proteins
include for instance calreticulin, glucose-regulated protein
78 (GRP78, also known as immunoglobulin-binding
protein or BiP), GRP94, and protein disulfide isomerase
(PDI). When the demand for protein folding increases
(e.g., enhanced protein synthesis, accumulation of mutated,
or abnormal proteins, etc) and exceeds protein folding
capacity, misfolded/unfolded proteins accumulate in the
ER lumen and trigger an ER stress. Many physiological or
pathological situations can interfere with protein folding
and can thus impact ER homeostasis such as alterations of
ER luminal calcium stores, energy depletion, redox distur-
bances, glucose starvation, lipid accumulation, viruses,
ethanol intoxication, and xenobiotics (Malhi and Kaufman
2011; Cnop et al. 2012; Cheng et al. 2013; Chen et al.
2014). Notably, ER stress is leading to the activation of the
so-called unfolded protein response (UPR), the role of
which is to maintain protein homeostasis by decreasing the
load of unfolded proteins and increasing the protein folding
capacity (Fig. 1). In addition, ER stress is also able to
activate autophagy- and proteasome-dependent proteolysis
when misfolded proteins are in excess (Hoyer-Hansen and
Ja¨a¨ttela¨ 2007; Digaleh et al. 2013).
UPR activation involves three different effectors (also
referred to as the 3 arms of the UPR): inositol requiring
1a (IRE1a), PKR-like ER kinase (PERK), and activating
transcription factor-6a (ATF6a) (Cawley et al. 2011; Dara
et al. 2011; Malhi and Kaufman 2011). One of the main
consequences of UPR activation is the inhibition of trans-
lation, in order to curb the synthesis of new proteins.
This response is mediated by the kinase PERK that phos-
phorylates the alpha subunit of eukaryotic translation-
initiation factor 2 (eIF2a) leading to a rapid reduction in
the initiation of mRNA translation and thus reducing the
load of new client proteins in the ER (Fig. 1).
Despite protein synthesis attenuation during ER stress,
there is a small subset of genes that are specifically
2016 | Vol. 4 | Iss. 1 | e00211
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transcribed and translated via the three branches of the
UPR (Fig. 1). For instance, these genes encode ER-asso-
ciated degradation (ERAD) proteins, ER chaperones (BiP/
GRP78 and GRP94), and enzymes able to expand protein
folding capacity including PDI and foldases (Kaufman
1999; Dara et al. 2011). This physiological response is also
called the adaptive UPR. In contrast, if the UPR is strong
enough and/or sustained, some deleterious consequences
can be observed such as apoptosis, which can be dependent
or not of mitochondria (Hom et al. 2007; Deniaud et al.
2008; Malhi and Kaufman 2011; Sano and Reed 2013).
Importantly, the mitochondrial-independent pathway of
apoptosis triggered by ER stress is the consequence of the
activation of different specific effectors such as the tran-
scription factor C/EBP homologous protein (CHOP, also
referred to as GADD153) and caspase 12 (Malhi and Kauf-
man 2011; Sano and Reed 2013). Depending of the stres-
sors, caspase 12 activation can require the translocation of
caspase 7 from the cytosol to the ER membranes, or a cal-
cium-mediated recruitment of calpain to the ER surface
(Nakagawa and Yuan 2000; Rao et al. 2001; Xie et al.
2002).
Another consequence of ER stress in some cells can
be the stimulation of lipid synthesis by activation of
different transcription factors such as sterol regulatory
element-binding proteins (SREBPs), CAAT/enhancer-
binding proteins (C/EBP) and peroxisome proliferator-
activated receptor-c (PPARc) (Werstuck et al. 2001;
Colgan et al. 2007; Malhi and Kaufman 2011; Lee et al.
2012). It is also important to point out that ER stress and
impaired protein folding can lead to the production of a
significant amount of ROS (Malhotra and Kaufman 2007;
Malhotra et al. 2008). Interestingly, it is estimated that
25% of the ROS generated in a cell results from the for-
mation of disulfide bonds in the ER during normal pro-
tein synthesis (Tu and Weissman 2004; Sevier and Kaiser
2008). Conversely, ROS accumulation can induce the oxi-
dation of resident ER proteins, including proteins of the
polypeptide folding machinery such as PDI and BiP (van
der Vlies et al. 2002, 2003), thus leading to an ER stress
and creating a vicious cycle (Malhotra and Kaufman
2007). To alleviate the deleterious effects of ROS, the
PERK branch of the UPR can activate the transcription of
several key antioxidant enzymes via the phosphorylation
Figure 1. The unfolded protein response (UPR). When an endoplasmic reticulum (ER) stress occurs, the cell initiates an adaptive response called
the UPR. It starts with the activation of three effectors, PKR-like ER kinase (PERK), IRE1, and ATF6, following the removal of the chaperone BiP
(GRP78) that maintains them in an inactivated state. PERK is a kinase which phosphorylates and inactivates the elongation initiation factor eIF2a,
leading to a general decrease in protein translation. However, eIF2a selectively stimulates the translation of ATF4, a transcription factor which
possesses a specific structure (uORF) on its mRNA. ATF4 then activates the synthesis of chaperones and proteins involved in autophagy, protein
secretion, and amino acid metabolism. IRE1 possesses a kinase activity leading to its autophosphorylation and activation of a RNAse activity. This
leads to the splicing of XBP1 mRNA, which is then translated into an active transcription factor. The transcription factor ATF6, which is bound to
the ER membranes as an inactive precursor is transferred via COPII-coated vesicles to the Golgi apparatus, where it is cleaved by the S1P and S2P
proteases into an active form. XBP1 and ATF6 will then activate in the nucleus the transcription of a set of factors allowing to restore ER
homeostasis including chaperones, foldases, and proteins involved in the degradation of unfolded polypeptides (ER-associated degradation). If
these mechanisms are not efficient to restore ER and cell homeostasis, the UPR will eventually activate mechanisms leading to cell apoptosis, in
particular via the transcription factor C/EBP homologous protein (CHOP).
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of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Cul-
linan and Diehl 2006; Flamment et al. 2012).
Drug-Induced ER Stress and Adverse Effects
Acetaminophen (APAP)
APAP is a popular drug for the management of pain and
hyperthermia (Table 1). Although APAP is usually deemed
as a safe drug, APAP intoxication after an overdose can lead
to massive hepatocellular necrosis and acute liver failure
(Craig et al. 2011). Moreover, there is evidence that the
maximum recommended dose (i.e., 4 g/day) can induce
mild to moderate hepatic cytolysis, even in healthy individ-
uals (Watkins et al. 2006; Winnike et al. 2010). APAP can
also induce acute kidney injury in some patients, either
after poisoning or at therapeutic doses (Blakely and
McDonald 1995; Kato et al. 2014). APAP-induced acute
nephrotoxicity manifests as acute tubular necrosis with
oliguric renal failure, which can occur alone or in associa-
tion with liver injury (Blakely and McDonald 1995; Jones
and Prescott 1997). APAP overdose has also been reported
to induce cardiotoxicity, pancreatitis, and ototoxicity
(Jones and Prescott 1997; Yorgason et al. 2011).
APAP is mainly metabolized in the liver into the non-
toxic glucuronide and sulfate conjugates. However, a
small amount of APAP is oxidized to the reactive
metabolite N-acetyl-p-benzoquinone imine (NAPQI) by
CYPs 2E1 (CYP2E1) and 3A4 (Gonzalez 2007; Aubert
et al. 2012). After its generation, NAPQI is normally
detoxified by glutathione (GSH) when APAP is taken at
the recommended dosage. After APAP overdose, or in the
presence of predisposing factors, high levels of NAPQI
can induce cytotoxicity. Indeed, once GSH is deeply
depleted and no longer available for NAPQI detoxication,
this reactive metabolite binds to different proteins, in par-
ticular at the mitochondrial level (Michaut et al. 2014).
This is followed by profound mitochondrial dysfunction
and ATP depletion, overproduction of ROS, c-jun
N-terminal kinase (JNK) activation, and massive hepato-
cellular necrosis (Jaeschke et al. 2012; Michaut et al.
2014). APAP-induced acute nephrotoxicity could also
involve CYP2E1-mediated generation of NAPQI, deple-
tion of GSH, and secondary oxidative stress (Hart et al.
1994; Das et al. 2010).
In vivo and in vitro investigations reported that APAP
was also able to induce an ER stress and that such delete-
rious effect could play an significant role in APAP-
induced cell death in liver, kidney, or inner ear (Lorz
et al. 2004; Nagy et al. 2007, 2010; Uzi et al. 2013;
Kalinec et al. 2014). In one of these studies, mortality
Figure 2. Potential mechanisms of drug-induced endoplasmic reticulum (ER) stress. Drugs are able to induce ER stress via different mechanisms including
proteasome inhibition, mitochondrial dysfunction, and alteration of key ER components. The latter mechanism is suspected with drugs that are
transformed into one or several reactive metabolites able to bind covalently to ER proteins and/or to induce oxidative damage of ER components secondary
to oxidative stress. Cytochromes P450 (CYPs) are often involved in the generation of reactive metabolites. The figure also indicates the respective targets of
thapsigargin and tunicamycin, which are two prototypical inducers of ER stress. Further information is provided in the text and Table 1.
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Table 1. Drugs for which adverse events have been linked to ER stress.
Drug(s) Pharmacological class Main side effects Mechanism of ER stress Additional information
Acetaminophen
(APAP)
Antalgic and antipyretic Hepatotoxicity and
nephrotoxicity, commonly
after an overdose
Currently unknown. Possible
involvement of the APAP-
derived reactive metabolite
NAPQI, which binds to
several key microsomal
proteins including PDI and
calreticulin
ER stress could be a late
event after APAP
intoxication, compared to
other deleterious events
such as mitochondrial
dysfunction and oxidative
stress
Amiodarone Antiarrhythmic and
antianginal
Hypotension, cutaneous
reactions, thyroid toxicity,
liver injury, and pulmonary
toxicity
Currently unknown ER stress could be involved
in some amiodarone-
induced adverse effects
(e.g., thyroid and lung
toxicity) in addition to
mitochondrial dysfunction
Arsenic trioxide
(As2O3)
Anticancer agent used to
treat acute promyelocytic
leukemia and other
hematologic malignancies
GI disorders, rash,
hematologic toxicity,
infections, cardiac toxicity
renal toxicity, myopathy,
neuropathy, and
hepatotoxicity
Possible involvement of
oxidative stress and
impairment of protein
folding
In addition to ER stress,
mitochondrial dysfunction
is also likely to be involved
in the pathogenesis of
some adverse effects
induced by arsenic trioxide
Bleomycin Anticancer drug used in
different malignancies such
as lymphomas, head and
neck cancers as well as
ovarian and testicular
cancers
GI disorders, cutaneous
reactions, myelosuppression,
and life-threatening
pulmonary toxicity
Currently unknown. Possible
mechanisms could involve
oxidative stress
ER stress could be involved
in bleomycin-induced
pulmonary toxicity
Bortezomib
(PS-341)
Anticancer drug used to treat
multiple myeloma and
mantle cell lymphoma
GI symptoms, fatigue,
peripheral neuropathy, and
thrombocytopenia
Proteasome inhibition ER stress is one mechanism
whereby bortezomib is able
to induced apoptosis in
cancer cells. ER stress could
be involved in bortezomib-
induced peripheral
neuropathy
Cisplatin Anticancer drug used in
various malignancies such as
testicular, gastric, lung,
breast, and ovarian cancers
GI disorders, kidney injury,
neurotoxicity,
hepatotoxicity, and
cardiotoxicity
Currently unknown. Possible
mechanisms could involve
oxidative stress and/or the
covalent binding of cisplatin
to key microsomal proteins
ER stress could be involved
in cisplatin-induced kidney
injury
Clozapine and
olanzapine
Antipsychotics GI disorders, drowsiness,
extrapyramidal symptoms,
elevation in liver enzymes,
and obesity (with related
metabolic disorders such as
insulin resistance and fatty
liver)
Currently unknown. Possible
involvement of increased
cytosolic calcium
Although fatty liver induced
by clozapine and
olanzapine could be
secondary to obesity,
hepatocyte ER stress
directly induced by these
drugs might also be
involved
Cyclosporin Immunosuppressant Infections, hypertension,
neurotoxicity,
nephrotoxicity, and
hepatotoxicity (including
cholestasis and cytolysis)
Currently unknown. In
hepatocytes, a possible
mechanism could be the
covalent binding of
cyclosporin metabolites to
pivotal microsomal proteins
Possible involvement of ER
stress in cyclosporin-
induced cholestasis.
Cyclosporin-induced ER
stress in kidney could be
indirect consequence of
vascular dysfunction
Diclofenac NSAID GI complications (including
gastric injury and intestinal
damage), hypersensitivity
Currently unknown. Possible
involvement of increased
intracellular calcium in
Possible involvement of ER
stress in diclofenac-induced
(Continued)
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Table 1. Continued.
Drug(s) Pharmacological class Main side effects Mechanism of ER stress Additional information
reactions, hepatotoxicity,
and kidney injury
gastric mucosal cells.
Because diclofenac
metabolism generates two
p-benzoquinone imines
similar to APAP-derived
NAPQI, binding to key ER
proteins could be involved
(in liver and other tissues
expressing CYPs)
GI complications and liver
toxicity
Efavirenz Antiretroviral (non-nucleoside
reverse transcriptase
inhibitor)
Rash, neuropsychological
symptoms, lipodystrophy,
and hepatotoxicity (in
particular cytolysis and
cholestasis)
Possible secondary
consequence of
mitochondrial dysfunction
and release of mitochondrial
calcium into the cytosol
Possible involvement of ER
stress in efavirenz-induced
hepatotoxicity
Erlotinib Anticancer drug used in
different malignancies
including non-small cell lung
cancer and pancreatic
cancer
Rash and GI manifestations
(in particular severe
diarrhea)
Currently unknown Possible involvement of ER
stress in erlotinib-induced
small intestinal injury and
diarrhea
Furosemide Diuretic used to treat
hypertension and edema
Dehydration, hypotension,
hyponatremia, and
hypokalemia
Currently unknown Hepatic ER stress has been
detected in mice treated by
furosemide. Extrapolation
to humans is doubtful since
this drug induces virtually
no hepatotoxicity in
patients
Indomethacin NSAID GI complications (including
gastric injury and intestinal
damage), hypersensitivity
reactions, hepatotoxicity,
and kidney injury
Currently unknown. Possible
involvement of increased
intracellular calcium (in
gastric mucosal cells)
Possible involvement of ER
stress in indomethacin-
induced GI complications
and liver toxicity
Paclitaxel (Taxol) Anticancer agent used in
different malignancies
including ovarian, breast,
and lung cancers
GI disorders, cardiac and
skeletal muscle toxicity,
myelosuppression,
neurotoxicity, and acute
liver injury (mostly hepatic
cytolysis)
Currently unknown Possible involvement of ER
stress in paclitaxel-induced
neurotoxicity
Protease inhibitors
(e.g., indinavir
and ritonavir)
Antiretroviral GI toxicity, rash, kidney
injury, hepatotoxicity
(including cytolysis,
cholestasis, and steatosis),
dyslipidemia, lipodystrophy,
insulin resistance, and type
2 diabetes
Possible involvement of
proteasome inhibition and
oxidative stress
Significant ER stress has
been showed with
atazanavir, indinavir,
lopinavir, nelfinavir,
ritonavir, and saquinavir,
but not with amprenavir,
darunavir, and tipranavir
Sertraline Antidepressant (selective
serotonin reuptake inhibitor)
Somnolence, GI disorders,
tremor, sexual dysfunction,
weight gain, and liver injury
Currently unknown. Possible
role of mitogen-activated
protein kinase (MAPK)
pathway activation
Possible involvement of ER
stress in sertraline-induced
hepatotoxicity
Thapsigargin Sesquiterpene lactone
isolated from the plant
Thapsia garganica, which
has long been used in
traditional Arabian
medicine
Severe skin irritation, salivary
hypersecretion,
gastroenteritis, nervous
disorders, and death
Inhibition of SERCA, thus
leading to severe calcium
depletion in the ER
Prototypical inducer of ER
stress. In addition to ER
stress, increase in free
cytosolic calcium is
inducing apoptosis in
different types of cells
treated with thapsigargin
(Continued)
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induced by a lethal dose of APAP (1 g/kg) was completely
prevented in CHOP knockout mice but data regarding
liver injury induced by a lower dose of this painkiller
(500 mg/kg) showed either a protection or no effect
depending of the route of APAP administration (Uzi
et al. 2013). In addition, other studies dealing with APAP
hepatotoxicity did not find markers of ER stress (Van
Summeren et al. 2011; Hur et al. 2012; van Summeren
et al. 2013). Actually, some data in mice indicated that
ER stress was a relatively late event after APAP intoxica-
tion (500 mg/kg), being significant only 12 hours follow-
ing APAP administration (Hur et al. 2012; Uzi et al.
2013). In contrast, mitochondrial alterations, ATP deple-
tion, JNK activation, oxidative stress, and increased
cytosolic calcium occurred much earlier in mouse liver
after the same dose of APAP (Burcham and Harman
1988; Jaeschke 1990; Ruepp et al. 2002; Aubert et al.
2012; Hur et al. 2012). Investigations in the human hep-
atoma HuH7 cell line also suggested that ER stress
induced by APAP occurred well after mitochondrial alter-
ations (Macanas-Pirard et al. 2005). Thus, further studies
are required to determine whether ER stress is a major
pathway involved in APAP toxicity and cell death.
The mechanism whereby APAP induces ER stress is
poorly understood. A first hypothesis could be the occur-
rence of microsomal alterations secondary to NAPQI gen-
eration. Indeed, it has been reported that APAP induced
severe GSH depletion, lipid peroxidation, and an oxida-
tive shift of the ER oxidoreductases ERp72 and PDI in
liver microsomes (Nagy et al. 2007; Letelier et al. 2011).
Furthermore, NAPQI can covalently bind to several
microsomal proteins such as GSH-S-transferase, PDI, and
calreticulin (Pumford et al. 1990; Weis et al. 1992; Zhou
et al. 1996; Shin et al. 2007). Because PDI and calreticulin
play a major role in protein folding and calcium seques-
tration within the ER (Coe and Michalak 2009), covalent
binding of NAPQI to these proteins could induce an ER
stress. Interestingly, it has been shown that other reactive
benzoquinones induced an ER stress (Wang et al. 2006).
Second, ER stress might also be a secondary consequence
of mitochondrial dysfunction, as discussed later on with
other drugs such as arsenic trioxide and efavirenz.
Amiodarone
This broad-spectrum antiarrhythmic drug also presents
an antianginal effect (Table 1). The main adverse effects
of amiodarone include hypotension, thyroid toxicity (hy-
per- or hypothyroidism), pulmonary toxicity including
bronchiolitis and pulmonary fibrosis, and hepatic lesions
such as steatosis, steatohepatitis, and cirrhosis (Dusman
et al. 1990; Fromenty and Pessayre 1995; Santangeli et al.
2012). Numerous studies have shown that mitochondrial
dysfunction is a major mechanism of amiodarone-
induced toxicity in liver and other tissues (Fromenty and
Pessayre 1995; Di Matola et al. 2000; Nicolescu et al.
2008; Begriche et al. 2011). Recently, amiodarone was
shown to induce ER stress in thyrocytes and lung epithe-
lial cells (Mahavadi et al. 2014; Lombardi et al. 2015),
but the involved mechanism was not determined in these
Table 1. Continued.
Drug(s) Pharmacological class Main side effects Mechanism of ER stress Additional information
Troglitazone Antidiabetic (via activation of
PPARc)
Severe and fatal liver injury
leading to the withdrawal
of troglitazone from the
market
Currently unknown. Possible
role of mitogen-activated
protein kinase (MAPK)
pathway activation
Possible involvement in
troglitazone-induced liver
injury in addition with
mitochondrial dysfunction
and oxidative stress
Tunicamycin Antibiotic active against
different bacteria, fungi,
and viruses
Major neurotoxicity and
death in animals. Kidney
and liver lesions are also
observed in the treated
animals
Impairment of glycosylation
of newly synthesized
proteins in the ER leading to
the disruption of their
folding
Prototypical inducer of ER
stress. Tunicamycin has
never been used in human
medicine due to its toxicity
Zidovudine (AZT) Antiretroviral (nucleoside
reverse transcriptase
inhibitor)
Lactic acidosis, myopathy,
and hepatotoxicity
(including cytolysis and
steatosis)
Currently unknown. Possible
impairment of proteasome
activity
Although ER stress could be
involved in steatosis, the
current knowledge points
to a major role of
mitochondrial dysfunction
in fat accretion induced by
zidovudine
ER, endoplasmic reticulum; CYPs, cytochromes P450; GI, gastrointestinal; PDI, protein disulfide isomerase; NAPQI, N-acetyl-p-benzoquinone imine;
NSAID, nonsteroidal anti-inflammatory drug; SERCA, sarcoplasmic/endoplasmic reticulum calcium ATPase; PPARc, peroxisome proliferator-activated
receptor-c.
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studies. In contrast, no ER stress was detected in hepato-
cytes treated with amiodarone, although it was observed
with cyclosporin A in the same investigations (Van Sum-
meren et al. 2011; van Summeren et al. 2013).
Arsenic Trioxide
Arsenic trioxide (As2O3) is used as an effective anticancer
drug for the treatment of acute promyelocytic leukemia
(APL) (Table 1). Interestingly, arsenic trioxide can be
effective in APL patients refractory to all-trans retinoic
acid and other conventional anticancer drugs such as
anthracyclines (Shen et al. 1997; Breccia and Lo-Coco
2012). This compound could also be useful in other
hematologic malignancies such as multiple myeloma and
myelodysplastic syndromes, although higher doses are
needed in these diseases (Douer and Tallman 2005;
Xu et al. 2014). As2O3 exerts its powerful therapeutic
effect in APL by promoting the degradation of a specific
oncogenic protein, the so-called PML-RARa fusion pro-
tein (Emadi and Gore 2010; Zhang et al. 2010). In con-
trast, regarding the other hematologic malignancies, this
drug could be effective by activating several pathways
leading to cancer cell apoptosis including mitochondrial
dysfunction, oxidative stress, and DNA damage (Pelicano
et al. 2003; Emadi and Gore 2010; Kumar et al. 2014; Xu
et al. 2014). Notably, some of these effects could be the
consequence of a direct interaction of arsenic trioxide
with GSH and protein thiols (Scott et al. 1993; Hughes
2002; Lu et al. 2007; Zhang et al. 2010). Some studies
also suggested that ER stress could be involved in the
anticancer action of arsenic trioxide (Du et al. 2006; Chen
et al. 2012; Chiu et al. 2015).
As2O3 can induce different adverse effects including GI
disorders, rash, hematologic toxicity (e.g., thrombocy-
topenia and neutropenia), infections, cardiac and renal
toxicity, myopathy, neuropathy, and hepatotoxicity
(Douer and Tallman 2005; Schiller et al. 2006; Echaniz-
Laguna et al. 2012). Some of these side effects can be seri-
ous and even fatal in a few cases (Westervelt et al. 2001;
Schiller et al. 2006). It is also noteworthy that chronic
arsenic poisoning via contaminated water and food is also
associated with a wide array of deleterious effects, which
overlap with arsenic trioxide toxicity (Yoshida et al. 2004;
Emadi and Gore 2010). Unsurprisingly, investigations in
noncancerous cells and in rodents suggested that some of
these side effects could be secondary to oxidative stress
and mitochondrial dysfunction (Aposhian and Aposhian
2006; Jomova et al. 2011; Mathews et al. 2013; Garcia-
Sevillano et al. 2014; Vineetha et al. 2015). Several studies
also showed that arsenic trioxide triggered ER stress in
different types of nonmalignant cells such as myoblasts,
vascular endothelial cells, pancreatic b-cells, neutrophils,
and macrophages (Binet et al. 2010; Lu et al. 2011; Yen
et al. 2012; Srivastava et al. 2013; Weng et al. 2014; King
et al. 2015). In several of these studies, ER stress was
associated with other deleterious events including loss of
the mitochondrial membrane potential, increased intracel-
lular free calcium, ROS overproduction, and apoptosis
(Lu et al. 2011; Yen et al. 2012; Srivastava et al. 2013;
Weng et al. 2014; King et al. 2015). Interestingly, arsenic
trioxide-induced ER stress could be prevented by the
GSH precursor N-acetylcysteine (Lu et al. 2011; Yen et al.
2012; Srivastava et al. 2013; King et al. 2015), or by the
mitochondrial-targeted antioxidant tiron (Weng et al.
2014). Since arsenic trioxide has been shown to increase
mitochondrial ROS production possibly via an impair-
ment of the respiratory chain (Paul et al. 2008; Vineetha
et al. 2015), ROS released from mitochondria could thus
play a significant role in arsenic trioxide-induced ER
stress. However, arsenic trioxide might also directly
induce ER stress because some authors showed with
in vitro assays that this compound was able to impair
protein folding (Ramadan et al. 2009; Jacobson et al.
2012).
Bleomycin
This anticancer drug is used to treat several types of
malignancies such as lymphomas, head, and neck cancers
as well as ovarian and testicular cancers (Table 1). Bleo-
mycin induces oxidative DNA damage and subsequent
cell death after formation of a complex with iron (or cop-
per) and oxygen, which generates free radicals able to cre-
ate DNA single- and double-strand breaks (Hecht 2000;
Chen and Stubbe 2005). Notably, this drug is also able to
oxidatively damage other cellular targets such as RNA,
proteins, and lipids (Chen and Stubbe 2005). Bleomycin-
induced adverse effects include GI disorders, myelosup-
pression, cutaneous reactions, and pulmonary toxicity, in
particular severe and life-threatening lung fibrosis (Frou-
darakis et al. 2013; Della Latta et al. 2015). The patho-
physiology of bleomycin lung toxicity seems complex, but
could involve oxidative stress, inflammation, and over-
production of profibrotic cytokine transforming growth
factor-b (TGFb) (Chen and Stubbe 2005; Kikuchi et al.
2011; Froudarakis et al. 2013; Della Latta et al. 2015).
Recent investigations suggested that ER stress could also
be involved (Zhao et al. 2014a,b; Tanaka et al. 2015). In
one of these studies, bleomycin-induced lung fibrosis was
significantly reduced in CHOP/ mice (Tanaka et al.
2015). Although the mechanism of bleomycin-induced ER
stress was not determined in these investigations, it is
conceivable that oxidative damage of key ER components
could be involved. In this regard, previous studies
reported that N-acetylcysteine was able to alleviate
2016 | Vol. 4 | Iss. 1 | e00211
Page 8
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
ER Stress in Drug-Induced Toxicity F. Foufelle & B. Fromenty
bleomycin-induced lung injury (Hagiwara et al. 2000;
Serrano-Mollar et al. 2003; Kikuchi et al. 2011).
Bortezomib
This anticancer drug is approved for the treatment of sev-
eral types of cancers including multiple myeloma and
mantle cell lymphoma (Table 1). The mechanism of
action of bortezomib (also known as PS-341) involves the
specific inhibition of proteasome, which is responsible for
cytotoxicity and apoptosis in cancer cells (Holkova and
Grant 2012; Dou and Zonder 2014). Indeed, proteasome
inhibition secondarily leads to ER stress, ROS production,
and activation of JNK and other signaling pathways
inducing cell death (Lee et al. 2003; Fribley et al. 2004;
Holkova and Grant 2012). The most frequent adverse
events with this drug are GI symptoms, peripheral neu-
ropathy, fatigue, and thrombocytopenia (Holkova and
Grant 2012; Argyriou et al. 2014). One study suggested
that bortezomib-induced ER stress could be involved in
peripheral neuropathy, possibly by impairing myelin syn-
thesis (Shin et al. 2010).
Cisplatin
Cisplatin, also known as cisplatinum or cis-diamminedi-
chloroplatinum (II) (CDDP), is an antitumor agent used
to treat various malignancies including testicular, gastric,
lung, breast, and ovarian cancers (Table 1). Although the
formation of cisplatin-DNA adducts is deemed to be a
key mechanism leading to cancer cell apoptosis, other
mechanisms independent of DNA damage could also be
involved such as ROS overproduction, increased plasma
membrane fluidity, and ER stress (Mandic et al. 2003;
Maccio and Madeddu 2013; Dasari and Tchounwou
2014).
Cisplatin treatment can induce several types of adverse
effects including GI disorders, kidney injury, neurotoxic-
ity, hepatotoxicity, and cardiotoxicity (Kitamura 2008;
Pabla and Dong 2008; Florea and B€usselberg 2011). Many
investigations have been performed to decipher the mech-
anisms of cisplatin-induced acute kidney injury because
this frequent adverse effect limits the use of cisplatin in
cancer therapy (Kitamura 2008; Pabla and Dong 2008).
The emerging picture to explain cisplatin-induced tubular
cell injury and death is a combination of different patho-
physiological events including mitochondrial dysfunction,
ROS overproduction, increased tumor necrosis factor-a
(TNFa) generation, and ER stress (Kruidering et al. 1997;
Kitamura 2008; Pabla and Dong 2008; Servais et al. 2008;
Mukhopadhyay et al. 2012). Indeed, markers of ER stress
such as increased BiP/GRP78 and CHOP expression
and caspase 12 activation have been found in different
investigations performed in renal cells and kidneys of
rodents treated with cisplatin (Liu and Baliga 2005; Pey-
rou et al. 2007; Khan et al. 2013; Kong et al. 2013; Gao
et al. 2014; Wang et al. 2014; Chen et al. 2015). Interest-
ingly, kidneys of CHOP/ mice showed less evidence of
cell death when treated with cisplatin (Zinszner et al.
1998). Despite these investigations, the precise mechanism(s)
whereby cisplatin is able to induce ER stress is still
unknown. Possible hypotheses could be cisplatin-induced
oxidative stress and/or irreversible binding of this drug to
key ER components. In this regard, cisplatin has been
shown to covalently bind to different proteins, including in
the microsomal compartment (Pattanaik et al. 1992; Litterst
and Schweitzer 1988; Huliciak et al. 2012).
Clozapine and olanzapine
These antipsychotic drugs are structurally similar to the
sedative and anxiolytic benzodiazepines (Table 1). The
antipsychotic action of clozapine and olanzapine is
deemed to be due to dopamine D2 receptor blockade,
although interactions with other neurotransmitter recep-
tors have been reported (Reynolds and Kirk 2010; Brosda
et al. 2014). The most common adverse effects of these
compounds include GI manifestations, drowsiness,
extrapyramidal symptoms, cardiac effects, elevation of
liver enzymes, and obesity, which can be associated with
insulin resistance and fatty liver (Melkersson and Dahl
2003; Begriche et al. 2011; De Fazio et al. 2015; Rojo
et al. 2015). Although clozapine- and olanzapine-induced
fatty liver could be secondary to obesity, investigations in
human hepatocytes also suggested a role of ER stress,
SREBP1c activation and increased hepatic lipogenesis,
possibly via a calcium-dependent pathway (Lauressergues
et al. 2012). Another study showed that olanzapine
induced ER stress and reduced insulin secretion in ham-
ster pancreatic b cells (Ozasa et al. 2013). However, the
pathophysiological significance of this effect remains
unclear since this drug classically induces hyperinsuline-
mia, even in the absence of weight gain (Melkersson and
Dahl 2003; Teff et al. 2013).
Cyclosporin
Cyclosporin (also known as cyclosporin A) is a potent
immunosuppressant isolated from the fungus Tolypocla-
dium inflatum (Table 1). This drug significantly improves
the short-term transplant survival by reducing the inci-
dence of acute allograft rejection. Like tacrolimus
(FK506), cyclosporin exerts its immunosuppressive effect
by inhibiting calcineurin, thus impairing the activation of
the nuclear factor of activated T cells (NFAT) signaling
pathway that plays a major role in T-cell-mediated
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adaptive immune response (Graham 1994; Jorgensen
et al. 2003). Unfortunately, cyclosporin treatment can
induce numerous side effects, which are sometimes severe
and require the discontinuation of the treatment. Besides
infections (that are the direct consequence of immuno-
suppression), cyclosporin can also induce hypertension,
neurotoxicity (e.g., paresthesia and tremor), nephrotoxic-
ity, and hepatotoxicity (Krupp and Monka 1990; Graham
1994; Servais et al. 2008). Liver toxicity not only includes
cholestasis but also hepatic cytolysis and steatosis (Biour
et al. 2004; Wang et al. 2013a).
Cyclosporin is extensively metabolized in liver and kid-
ney by several CYPs, which generate at least 30 different
metabolites (Kelly et al. 1999; Zheng et al. 2013). Some
of these metabolites are able to form stable adducts with
cellular proteins indicating that they are highly reactive
in nature (Nagelkerke et al. 1987; Sadrieh and Thomas
1994; Christians and Sewing 1995). Notably, oxidative
stress seems to be an important mechanism whereby
cyclosporin can lead to cytolysis in different cell types
(Wolf et al. 1997; Nishida et al. 2003; Navarro-Antolin
et al. 2007) and to kidney or liver damage in treated
rodents (Tariq et al. 1999; Kaya et al. 2008; Haleagrahara
et al. 2009). Cyclosporin-induced oxidative stress could
be the consequence of mitochondrial dysfunction and
reduced antioxidant defenses (Kaya et al. 2008; Palomero
et al. 2001; Redondo-Horcajo et al. 2010; Xiao et al.
2013).
Several studies carried out in mouse hepatocytes and
the human hepatoma cell lines HepG2 and HepaRG
showed that cyclosporin was able to induce an ER stress
(Van Summeren et al. 2011; van Summeren et al. 2013;
Szalowska et al. 2013; van den Hof et al. 2014; Sharanek
et al. 2014). Interestingly, the investigations performed in
HepaRG cells showed that reduced canalicular efflux of
taurocholate induced by high concentrations (50 lmol/L)
of cyclosporin were alleviated by 4-phenylbutyrate (4-
PBA), a chemical chaperone commonly used to protect
against ER stress (Sharanek et al. 2014). However, lower
concentrations of cyclosporin (10 lM) impaired tauro-
cholate canalicular efflux without inducing ER stress
(Sharanek et al. 2014). Notably, several studies showed
that cyclosporin is a potent inhibitor of the bile salt
export pump (BSEP) (Dawson et al. 2012; Pedersen et al.
2013). Thus, these investigations suggest that cyclosporin-
induced impairment of bile acid efflux and cholestasis
could be secondary to ER stress only for high concentra-
tions of this immunosuppressant. Whether ER stress plays
a role in cyclosporin-induced hepatic cytolysis and steato-
sis has not been addressed in the aforementioned studies.
Moreover, it is still unknown how cyclosporin can induce
ER stress in liver. A first mechanism could involve CYP-
mediated generation of reactive metabolites able to alter
key ER proteins since some of these metabolites can bind
covalently to microsomal proteins (Nagelkerke et al. 1987;
Sadrieh and Thomas 1994). Another mechanism might be
the occurrence of oxidative stress and lipid peroxidation
within the ER (Barth et al. 1991; Serino et al. 1993).
Different in vitro and in vivo investigations also
attempted to determine whether ER stress could be an
important mechanism involved in cyclosporin-induced
nephrotoxicity (Han et al. 2008; Pallet et al. 2008; Lhotak
et al. 2012; Sarro et al. 2012; Liu et al. 2015). These stud-
ies performed in cultured renal proximal tubule cells and
kidneys of treated rats clearly showed that this immuno-
suppressant agent was able to induce an ER stress (e.g.,
activation of CHOP, BiP/GRP78, and GRP94). In addi-
tion, markers of ER stress have been found in renal biop-
sies of patients with cyclosporin-induced acute or chronic
nephrotoxicity (Lhotak et al. 2012; Hama et al. 2013).
However, despite these data, a direct causal relationship
between cyclosporin-induced ER stress and nephrotoxicity
is doubtful. Indeed, numerous experimental and clinical
studies provided strong evidence that cyclosporin-induced
nephrotoxicity is mainly the consequence of reduced renal
blood flow due to afferent and efferent arteriolar vasocon-
striction (English et al. 1987; Kon et al. 1990; Smith et al.
1992; Grieve et al. 1993; Pannu and Nadim 2008). Since
hypoxia can induce an ER stress in particular in the kid-
ney (Inagi et al. 2014; Suh et al. 2014), renal ER stress
observed during cyclosporin nephrotoxicity could be a
mere consequence of vascular dysfunction induced by this
drug. Finally, it is noteworthy that cyclosporin is not able
to bind covalently to microsomal proteins in kidney, con-
trary to what happens in liver microsomes (Nagelkerke
et al. 1987; Sadrieh and Thomas 1994).
Diclofenac and indomethacin
The nonsteroidal anti-inflammatory drugs (NSAIDs)
diclofenac and indomethacin are discussed together
because of their similar pharmacological and toxicological
profiles (Table 1). Indeed, these drugs are potent nonse-
lective inhibitors of the cyclooxygenases 1 and 2 (COX1
and COX2) used for the treatment of chronic inflamma-
tory diseases such as osteoarthritis and rheumatoid arthri-
tis. As many other nonselective COX inhibitors, the most
significant side effects induced by diclofenac and indo-
methacin are GI complications such as bleeding and
ulceration, hypersensitivity reactions (e.g., anaphylaxis,
skin eruptions, and bronchospasms), and kidney injury
(Rossi et al. 1985; Richy et al. 2004; Gonzalez et al. 2009;
Castellsague et al. 2012; Wallace 2012). These drugs can
also induce hepatotoxicity, mostly cytolytic hepatitis and
cholestasis (Banks et al. 1995; Biour et al. 2004; Wang
et al. 2013a).
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The most common NSAID-induced GI toxicity seems
to be gastric injury, albeit intestinal damage could also be
a frequent side effect observed in treated patients (Wal-
lace 2012; Boelsterli et al. 2013). Numerous studies have
shown that a major mechanism of NSAID-induced gas-
tropathy is COX inhibition and the secondary decreased
production of mucosal prostaglandins, which have a
major cytoprotective action on the gastric mucosa (Rains-
ford and Willis 1982; Wallace 2012; Seminerio et al.
2014). Nevertheless, some investigations suggested that
ER stress could also be involved for some NSAIDs includ-
ing diclofenac and indomethacin (Tsutsumi et al. 2004;
Ohyama et al. 2012). In one of these studies, indometha-
cin-induced apoptosis in guinea-pig gastric mucosal cells
was partially but significantly prevented by expression of
a dominant-negative form of CHOP (Tsutsumi et al.
2004). One mechanism whereby some NSAIDs are able to
induce ER stress and apoptosis in gastric mucosal cells
could be an increase in intracellular calcium levels sec-
ondary to membrane permeabilization (Tanaka et al.
2005).
Contrary to NSAID-induced gastropathy, COX inhibi-
tion does not seem to play a primary role in NSAID-
induced enteropathy, although decreased prostaglandin
synthesis could render the intestine more susceptible to
injury. Indeed, oxidative stress, mitochondrial dysfunc-
tion, and TNFa release could be important mechanisms
in NSAID enteropathy (Wallace 2012; Boelsterli et al.
2013). Recent investigations carried out in rat intestinal
slices suggested that diclofenac could be toxic via an ER
stress in addition to mitochondrial injury and oxidative
stress (Niu et al. 2014). ER stress was also observed in
cultured rat enterocytes treated with indomethacin (Nara-
bayashi et al. 2015).
An important mechanism of diclofenac-induced hepa-
tocellular injury is the CYP-mediated generation of two
p-benzoquinone imines and possibly other reactive
metabolites triggering oxidative stress, mitochondrial dys-
function, and cell death (Bort et al. 1999; Boelsterli 2003;
Park et al. 2005). In addition, diclofenac is able to induce
direct mitochondrial dysfunction (Begriche et al. 2011;
Porceddu et al. 2012; Massart et al. 2013). Although ER
stress with CHOP induction has been observed in hepatic
cells treated with diclofenac (Franceschelli et al. 2011;
Nadanaciva et al. 2013; Fredriksson et al. 2014), it is still
unclear whether this event plays a primary role in diclofe-
nac-induced cell demise, compared to mitochondrial dys-
function. Moreover, the mechanism whereby diclofenac
induces ER stress in hepatocytes is still unknown.
Although diclofenac was shown to bind irreversibly to
hepatic microsomal proteins in several studies (Kretz-
Rommel and Boelsterli 1994; Hargus et al. 1995;
Obach et al. 2008), the targeted polypeptides are still
unidentified. It will be interesting to determine whether
diclofenac-derived p-benzoquinone imines can bind cova-
lently to the microsomal PDI and calreticulin, as does
APAP-derived NAPQI (Zhou et al. 1996). Finally, it is
noteworthy that indomethacin was also found to induce
ER stress in hepatic cells (Franceschelli et al. 2011). How-
ever, similar to diclofenac, it is still unclear whether ER
stress is the primary mechanism of liver injury induced
by indomethacin since this drug is also able to directly
impair mitochondrial function (Jacob et al. 2001; Por-
ceddu et al. 2012).
Efavirenz
Efavirenz is a non-nucleoside reverse transcriptase inhibi-
tors (NNRTIs) used to treat the human immunodefi-
ciency virus (HIV) infection (Table 1). Efavirenz can
induce several types of side effects including neuropsycho-
logical manifestations (e.g., dizziness, headache, and
depression), rash, lipodystrophy and hepatotoxicity,
which can occur as hepatic cytolysis and cholestasis (Sulk-
owski et al. 2002; Biour et al. 2004; Maggiolo 2009; Mar-
golis et al. 2014). Several studies also suggest that
efavirenz could trigger endothelial dysfunction and
increase the cardiovascular risk in HIV-infected patients
(Maggi et al. 2011; Gupta et al. 2012). The exact mecha-
nism whereby efavirenz can be toxic is still unclear. Sev-
eral studies showed that efavirenz can induce
mitochondrial dysfunction in different experimental mod-
els including human hepatic cells (Apostolova et al. 2010;
Blas-Garcıa et al. 2010), primary rat neurons (Purnell and
Fox 2014) and different brain regions of treated mice
(Streck et al. 2011). A recent study reported that efavirenz
was able to induce an ER stress in human hepatic Hep3B
cells, with an upregulation of CHOP, BiP/GRP78, and
phospho-eIF2a (Apostolova et al. 2013). However, inves-
tigations demonstrated that this deleterious effect was
actually secondary to mitochondrial dysfunction and the
release of mitochondrial calcium into the cytosol (Apos-
tolova et al. 2013). Two recent studies also showed that
efavirenz-induced ER stress in human endothelial cells
(Bertrand and Toborek 2015; Weiß et al. 2015), but the
involved mechanism was not determined in these investi-
gations.
Protease inhibitors
Protease inhibitors (PIs) are antiretroviral drugs fre-
quently used for the treatment of HIV-infected patients
(Table 1). This important pharmacological class includes
numerous compounds such as amprenavir, atazanavir,
darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saqui-
navir, and tipranavir. Taken as a whole, these drugs can
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induce GI toxicity such as nausea and diarrhea, rash, liver
and kidney injury, dyslipidemia, lipodystrophy, insulin
resistance, and type 2 diabetes (Gougeon et al. 2004;
Pannu and Nadim 2008; Izzedine et al. 2009; Caron-
Debarle et al. 2010; Margolis et al. 2014). As regards hep-
atotoxicity, different types of lesions have been described
in treated patients such as cytolysis, cholestasis, steatosis,
and cirrhosis (Biour et al. 2004; Wang et al. 2013a). Some
PIs such as indinavir, lopinavir, and ritonavir are sus-
pected to increase the risk of cardiovascular diseases
including myocardial infarction (Bavinger et al. 2013;
Margolis et al. 2014).
PIs are toxic via different pathways, in particular by
inducing mitochondrial dysfunction and oxidative stress
and by promoting inflammation (Gougeon et al. 2004;
Caron et al. 2007; Caron-Debarle et al. 2010; Mencarelli
et al. 2012; Bociaga-Jasik et al. 2013; Cassol et al. 2013;
Reyskens et al. 2013). Several studies also reported that
some PIs are able to induce ER stress in different types of
cells (e.g., macrophages, adipocytes, hepatocytes) and
tissues (e.g., liver, intestine) (Zhou et al. 2005; Gupta
et al. 2007; Cao et al. 2010; Touzet and Philips 2010; Wu
et al. 2010; Zha et al. 2010, 2013; Br€uning 2011; Zhou
2011; Br€uning et al. 2012; Apostolova et al. 2013; Taura
et al. 2013; Wang et al. 2013b). In these investigations,
ER stress was consistently observed with atazanavir, indi-
navir, lopinavir, nelfinavir, ritonavir, and saquinavir. In
contrast, amprenavir, darunavir, and tipranavir induced
only a weak or no ER stress in the different tested experi-
mental models (Wu et al. 2010; Zhou 2011; Taura et al.
2013; Zha et al. 2013). Notably, some of these studies
brought evidence that PI-induced ER stress was involved
in lipid metabolism alterations, inflammation, cell apop-
tosis, and tissue damage, in particular by using CHOP/
mice or cells (Zhou et al. 2005; Cao et al. 2010; Wu et al.
2010; Zha et al. 2010, 2013; Zhou 2011; Wang et al.
2013b). According to these investigations, ER stress could
thus be an important mechanism whereby some PIs are
able to induce metabolic disturbances such as lipodystro-
phy, hepatic steatosis and cytolysis, dyslipidemia, and
some cardiovascular complications. Lastly, it is notewor-
thy that PI-induced ER stress and hepatocyte damage
have been shown to be potentiated by ethanol exposure
(Kao et al. 2012; Hu et al. 2015). Interestingly, one of
these studies reported that the combination of PIs and
ethanol significantly induced ER stress and cell death in
mouse hepatocytes but not in mouse Kupffer and stellate
cells (Hu et al. 2015). These experimental data could be
clinically relevant because previous investigations reported
a greater risk of PI-induced severe hepatic injury in
patients abusing alcohol (Nunez et al. 2001).
The precise mechanisms whereby some PIs can induce
ER stress is still unclear, although two hypotheses have
been proposed. The first mechanism could be PI-induced
inhibition of proteasome activity (Parker et al. 2005;
Pyrko et al. 2007; Bono et al. 2012). Indeed, several stud-
ies carried out with other compounds (e.g., bortezomib)
showed that specific impairment of proteasome function
can potently trigger ER stress (Lee et al. 2003; Fribley
et al. 2004; Bono et al. 2012). In this context, ER stress
occurs because the proteasome cannot degrade the few
misfolded proteins that are normally but constantly pro-
duced within the ER (Fribley and Wang 2006; Xu et al.
2005). Proteasome inhibition has been shown for atazana-
vir, indinavir, lopinavir, nelfinavir, ritonavir, and saquina-
vir, although the potency of this inhibitory effect seemed
variable between these drugs (Schmidtke et al. 1999;
Pajonk et al. 2002; Piccinini et al. 2002; Parker et al.
2005; Bono et al. 2012). The second potential mechanism
could involve PI-induced oxidative stress, as suggested by
some investigations (Touzet and Philips 2010; Taura et al.
2013). However, the precise origin of oxidative stress has
not been addressed in these studies.
Thapsigargin
This sesquiterpene lactone of the Mediterranean plant
Thapsia garganica is a prototypical and powerful inducer
of ER stress (Zinszner et al. 1998; Rutkowski et al. 2008;
Kammoun et al. 2009) (Table 1). More precisely, thapsi-
gargin induces ER stress by inhibiting sarcoplasmic/endo-
plasmic reticulum calcium ATPase (SERCA) (Fig. 2),
thus leading to severe depletion of ER calcium (Kaufman
1999; Denmeade and Isaacs 2005; Sch€onthal 2012). In
addition to ER stress-induced activation of downstream
effectors that can trigger cell death, the concomitant
increase in free cytosolic calcium is also a potent
proapoptotic signal in different types of cells (Jiang et al.
1994; Treiman et al. 1998; Kim et al. 2008). In mast cells,
thapsigargin-induced augmentation in cytosolic calcium
is leading to the release of histamine, which could
explain the potent skin irritating effects of Thapsia gar-
ganica (Jacobsen et al. 1987; Doan et al. 2015). Other
toxic effects of this plant can include salivary hypersecre-
tion, gastroenteritis, vomiting and diarrhea, nervous dis-
orders, fever, and death in the most severe cases of
intoxication (Bnouham et al. 2006; Hammiche et al.
2013). Despite its significant toxicity, Thapsia garganica
has long been used in traditional Arabian medicine for
the treatment of different illnesses including rheumatic
pains, women infertility, and pulmonary diseases (Trei-
man et al. 1998; Bnouham et al. 2006; Hammiche et al.
2013). In the past few years, different thapsigargin ana-
logs have been developed as potential drug candidates for
the treatment of prostate cancers (Isaacs 2005; Dubois
et al. 2013; Doan et al. 2015).
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Tunicamycin
This glucosamine-containing antibiotic produced by
Streptomyces lysosuperificus is active against different types
of microorganisms including gram-positive bacteria,
fungi, yeast, and viruses (Table 1). Early investigations
have demonstrated that this antibiotic was able to inhibit
the synthesis of N-glycoproteins in yeast and bacteria
(Kuo and Lampen 1974; Bettinger and Young 1975) as
well as in animals and plants (Fig. 2) (Takatsuki and
Tamura 1971; Tkacz and Lampen 1975; Ericson et al.
1977). More specifically, tunicamycin impairs the transfer
of N-glucosamine to the polyisoprenoid lipid dolichol
phosphate, the first step in the synthesis of the lipid-
linked oligosaccharide that is used as a precursor for the
N-glycoproteins (Ericson et al. 1977; Bieberich 2014).
Notably, this biosynthetic step takes place within the ER
in eukaryotic cells (Bieberich 2014). Consequently,
impairment of glycosylation of newly synthesized proteins
is leading to the disruption of their folding in the ER
(Kaufman 1999; Sch€onthal 2012). In addition, this alter-
ation of peptide conformation can secondarily prevent
the cellular secretion of some proteins such as different
immunoglobulins (Hickman et al. 1977; Elbein 1981).
Tunicamycin has never been used in human medicine
because of its major toxicity. In particular, acute tuni-
camycin administration in rodent, cattle and sheep is
leading to severe neurotoxicity with disturbed conscious-
ness, convulsions, and paralysis, which can occasionally
lead to the death of the treated animals (Leaver et al.
1988; Bourke and Carrigan 1993). The lesions in the brain
are mainly vascular and it is deemed that blood vessel
damage could secondary lead to brain ischemia and
hypoxic neuronal damage (Finnie and O’Shea 1988; Lea-
ver et al. 1988). Indeed, tunicamycin damages the
endothelial cells of small blood vessels with marked
dilatation of the rough ER (i.e., typical of the presence of
ER stress), which appears to strongly distort their cyto-
plasm and cause stenosis of the blood vessel lumen (Fin-
nie and O’Shea 1988; Finnie and O’Shea 1990a).
Tunicamycin-induced direct endothelial toxicity has also
been observed in vitro in vascular endothelial cells (Finnie
and O’Shea 1990a; Galan et al. 2014; Suganya et al.
2014). Nevertheless, in vitro studies also showed that tuni-
camycin can induce neuronal cell death in different types
of neurons (Chang and Korolev 1996; Kosuge et al. 2006;
Galehdar et al. 2010). Some of these in vitro investigations
demonstrated that tunicamycin-induced endothelial and
neuronal cell death was linked to ER stress (Kosuge et al.
2006; Galehdar et al. 2010; Suganya et al. 2014).
In addition to its neurotoxicity, tunicamycin is also
able to induce acute liver and kidney injuries in the
intoxicated animals (Zinszner et al. 1998; Finnie and
O’Shea 1989; Finnie and O’Shea 1990b; Marciniak et al.
2004; Rutkowski et al. 2008; Carlisle et al. 2014). Notably,
tunicamycin-induced acute kidney injury is blunted in
CHOP knockout mice, or in mice treated with the chemi-
cal chaperone 4-PBA (Marciniak et al. 2004; Carlisle et al.
2014). In liver, the lesions observed in tunicamycin-
intoxicated animals include steatosis, bile ductular hyper-
plasia, swollen hepatocytes, and the presence of apoptotic
bodies (Finnie and O’Shea 1989; Finnie and O’Shea
1990b; Finnie et al. 2004; Rutkowski et al. 2008). Interest-
ingly, swollen hepatocytes are characterized by a marked
dilatation of the rough ER (Finnie and O’Shea 1989; Fin-
nie et al. 2004). The precise mechanism of tunicamycin-
induced hepatic steatosis is still elusive. Although some
data suggested that tunicamycin could favor de novo lipo-
genesis in particular via a SREBP1c-dependent pathway
(Kammoun et al. 2009; Lee et al. 2012), other investiga-
tions did not support this mechanism (Rutkowski et al.
2008; Jo et al. 2013). Alternatively, tunicamycin could
favor intrahepatic lipid accumulation by other mecha-
nisms including reduced expression and activity of the
transcription factor PPARa, a master regulator of fatty
acid oxidation (Rutkowski et al. 2008; Yamamoto et al.
2010; Chikka et al. 2013), impairment of triglyceride
excretion (Zhang et al. 2011), or increased lipid delivery
to the liver (Jo et al. 2013; Bogdanovic et al. 2015).
Zidovudine
This nucleoside reverse transcriptase inhibitor (NRTI) is
the first antiretroviral drug marketed for the treatment of
HIV (Table 1). Other NRTIs include stavudine (d4T),
lamivudine (3TC), didanosine (ddI), and tenofovir.
Despite their pharmacological interest, these drugs can
unfortunately induce a large array of side effects, which
are sometimes fatal, such as hepatotoxicity, renal dysfunc-
tion, myopathy, pancreatitis, peripheral neuropathy,
lipodystrophy, and lactic acidosis (Izzedine et al. 2009;
Caron-Debarle et al. 2010; Begriche et al. 2011; Margolis
et al. 2014). NRTI-induced liver injury includes hepatic
cytolysis, microvesicular and/or macrovacuolar steatosis,
steatohepatitis, and cirrhosis (Biour et al. 2004; Massart
et al. 2013; Wang et al. 2013a). Numerous investigations
have shown that the main mechanism involved in NRTI
toxicity is mitochondrial dysfunction, as these drugs can
reduce mitochondrial DNA (mtDNA) levels in various
tissues via DNA polymerase c inhibition (Gaou et al.
2001; Igoudjil et al. 2006; Schon and Fromenty 2016). A
recent study showed that zidovudine-induced hepatic
steatosis in mice was associated with an ER stress, with a
concomitant increase in SREBP1c expression and reduced
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PPARa expression (Banerjee et al. 2013). However,
mtDNA levels and mitochondrial function were not mea-
sured in this study and thus it remains unclear whether
zidovudine-induced ER stress was the main mechanism of
fat accumulation in mouse liver. In addition, the mecha-
nism whereby zidovudine could induce an ER stress is
still unknown, although a previous study showed that this
drug was able to significantly inhibit the proteasome
activity (Piccinini et al. 2002).
Other drugs
The antidepressant sertraline and the antidiabetic troglita-
zone can be toxic for the liver (Table 1) (Biour et al.
2004; Wang et al. 2013a). Importantly, troglitazone
caused several cases of fatal liver failure and was thus
withdrawn from the market (Labbe et al. 2008). The role
and mechanisms of ER stress in sertraline and troglita-
zone-induced hepatotoxicity have been discussed in a
recent review (Chen et al. 2014). Hepatic ER stress has
also been detected in a mouse model of liver toxicity
induced by the diuretic drug furosemide (Table 1) (Qu
et al. 2014). However, extrapolation of these experimental
data to humans is doubtful because furosemide induces
virtually no hepatotoxicity in treated patients (Biour et al.
2004; McGill et al. 2015).
Erlotinib is an anticancer drug that can induce severe
diarrhea requiring an interruption of the treatment
(Table 1) (Reck et al. 2011). A recent study provided
some evidence that erlotinib-induced ER stress in rat
small intestine epithelial cells was involved in apoptosis
and reduced expression of E-cadherin (Fan et al. 2014).
These effects might explain why erlotinib can impair the
gut barrier integrity and induce diarrhea (Fan et al.
2014). ER stress could also be involved in the neuronal
toxicity of the anticancer drug paclitaxel (Table 1) (Tan-
imukai et al. 2013), in addition to microtubule stabiliza-
tion (Gornstein and Schwarz 2014).
Concluding Remarks and Remaining Issues
The present review underlines that ER stress could be
involved in different adverse effects induced by drugs
belonging to different pharmacological classes. However, it
is still unclear whether ER stress is a common key patho-
physiological signal involved in drug-induced toxicity. This
may be because ER stress has not been frequently assessed
in the context of drug-induced side effects, in contrast to
other mechanisms of toxicity such as mitochondrial dys-
function and oxidative stress. It is also noteworthy that a
great number of studies reported only a mere association
between ER stress and cellular (or tissue) alterations.
Hence, it is difficult to ascertain from these reports that ER
stress is bona fine involved in drug-induced toxicity. In con-
trast, some of the aforementioned studies brought causal
relationship by using CHOP-/- mice or cells (Zinszner et al.
1998; Marciniak et al. 2004; Wu et al. 2010; Zhou 2011;
Uzi et al. 2013; Wang et al. 2013b; Zha et al. 2013; Tanaka
et al. 2015). Thus, future investigations should use these
experimental models, or similar ones with knockout of
other major proteins involved in ER stress such as IRE1,
PERK, or ATF6 (Fig. 1).
As previously mentioned, some investigators used
4-PBA in order to determine whether this chemical chap-
erone could alleviate drug-induced cellular (or tissue)
damage. However, besides being protective against ER
stress, 4-PBA presents other biological effects. For
instance, 4-BPA was shown to be a histone deacetylase
(HDAC) inhibitor and an autophagy inducer, to regulate
Hsp70 expression and to present antioxidant and anti-
inflammatory properties (Iannitti and Palmieri 2011;
Suaud et al. 2011; Roy et al. 2012; Rekha et al. 2015).
Thus, protection afforded by 4-BPA might not be fully
related to ER stress defense.
In some studies, the presence of ER stress is based on
the assessment of only a few UPR markers such as BiP/
GRP78 and CHOP. However, accurate ER stress monitor-
ing should include several markers activated by the three
canonical arms of the UPR, as underscored in previous
reviews (Samali et al. 2010; Cawley et al. 2011; Hiramatsu
et al. 2011). Since the detection of cleaved ATF6, phos-
pho-PERK, and phospho-IRE1 is rather difficult, different
downstream targets of these three effectors can be studied
(Samali et al. 2010). Hence, in addition to BiP/GRP78
and CHOP, other UPR markers should be investigated at
the mRNA and/or protein level such as spliced X-box
binding protein 1 (XBP1), homocysteine-inducible ER
protein (HERP), ER degradation enhancer mannosidase
alpha-like 1 (EDEM1), phospho-eIF2a, and ATF4 (Samali
et al. 2010; Cawley et al. 2011; Hiramatsu et al. 2011). In
addition, investigations on drug-induced ER stress should
systematically include a positive control such as tuni-
camycin or thapsigargin.
It must be also pointed out that the exact mechanism
of ER stress was not addressed in most of the studies
cited in this review. In contrast, investigations performed
with a few drugs suggested that ER stress could be sec-
ondary to oxidative stress (i.e., arsenic trioxide), protea-
some inhibition (i.e., bortezomib), or increased cytosolic
calcium (i.e., efavirenz) (Fig. 2). The data reported with
efavirenz are particularly interesting because ER stress and
elevated cytosolic calcium were found to be secondary to
mitochondrial dysfunction (Apostolova et al. 2013).
Notably, mitochondrial dysfunction induced by other fac-
tors including toxins can secondarily cause an augmenta-
tion in cytosolic calcium (Luo et al. 1997; Sheehan et al.
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1997; Biswas et al. 1999; Amuthan et al. 2002). Since
numerous drugs are able to impair mitochondrial func-
tion (Labbe et al. 2008; Begriche et al. 2011; Porceddu
et al. 2012; Jones et al. 2014), it will be important to
determine whether some of these drugs are also able to
induce an ER stress by increasing cytosolic calcium.
Another mechanism of drug-induced ER stress that
deserves to be carefully addressed is the covalent binding
of reactive metabolites to ER proteins (Fig. 2). Indeed,
drugs can be toxic because of their biotransformation by
CYPs into one or several reactive metabolites, as previ-
ously discussed. Importantly, CYPs are mainly located in
the ER membranes, although some CYPs could be also
found in mitochondria (Avadhani et al. 2011; Knockaert
et al. 2011). In addition, it is noteworthy that CYPs are
expressed in various tissues, as previously mentioned.
Thus, covalent binding of reactive metabolites to ER pro-
teins could occur with some drugs in different tissues and
might lead to ER stress and side effects.
Mitochondrial dysfunction can secondarily lead to ER
stress, as previously mentioned. However, a reciprocal
relationship has also been showed in some pathophysio-
logical situations. For instance, ER stress induced by thap-
sigargin and tunicamycin can secondarily promote
mitochondrial calcium accumulation and opening of the
mitochondrial permeability transition (MPT) pore as well
as other mitochondrial alterations leading to cell death
(Hom et al. 2007; Deniaud et al. 2008). Actually, there is
a close connection between ER and mitochondria and the
physical association of the two organelles creates a struc-
ture known as the mitochondria-associated ER membrane
(MAM) (Csordas et al. 2006; Hayashi et al. 2009). In the
physiological context, this connection allows a constant
transfer of calcium between ER and mitochondria (Csor-
das et al. 2010; Giacomello et al. 2010). During ER stress,
calcium can be massively transferred to the mitochondria
through these ER-mitochondria microdomains, or as a
consequence of increased cytosolic calcium (Mandic et al.
2003; Benali-Furet et al. 2005; Deniaud et al. 2008; Tim-
mins et al. 2009). Hence, induction of ER stress can sec-
ondarily augment the mitochondrial overload of calcium
and thus favor mitochondrial membrane permeabilization
and the release of proapoptotic factors such as cyto-
chrome c and apoptosis-inducing factor (Deniaud et al.
2008; Pinton et al. 2008; Timmins et al. 2009; Fonseca
et al. 2013). In the context of drug-induced toxicity, it
will thus be important to gain more information regard-
ing the relationship between ER stress and mitochondrial
dysfunction and to determine whether some drugs can
specifically interact with MAM. This may help to find
strategies to prevent, or alleviate, some adverse effects that
can be severe and life-threatening in some patients.
Disclosure
None declared.
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